Gene:
SLC19A2
solute carrier family 19 (thiamine transporter), member 2

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  TRMA
Alternate Symbols:  THTR1
PharmGKB Accession Id: PA35825

Details

Cytogenetic Location: chr1 : q23.3 - q24.2
GP mRNA Boundary: chr1 : 169433147 - 169455208
GP Gene Boundary: chr1 : 169430147 - 169465208
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Publications related to SLC19A2: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation. PloS one. 2009. Hesselson Stephanie E, et al. PubMed

LinkOuts

Entrez Gene:
10560
OMIM:
249270
603941
UCSC Genome Browser:
NM_006996
RefSeq RNA:
NM_006996
RefSeq Protein:
NP_008927
RefSeq DNA:
AC_000044
AC_000133
NC_000001
NG_008255
NT_004487
NW_001838533
NW_926128
UniProtKB:
S19A2_HUMAN (O60779)
Ensembl:
ENSG00000117479
GenAtlas:
SLC19A2
GeneCard:
SLC19A2
MutDB:
SLC19A2
ALFRED:
LO080701Q
HuGE:
SLC19A2
Comparative Toxicogenomics Database:
10560
ModBase:
O60779
HumanCyc Gene:
HS04138
HGNC:
10938

Common Searches